Aims: Despite the established prognostic relevance of tumour budding in colorectal cancer, the reproducibility of the methods reported for its assessment has not yet been determined, limiting its use and reporting in routine pathology practice. Methods and results: A morphometric system within telepathology was devised to evaluate the reproducibility of the various methods published for the assessment of tumour budding in colorectal cancer. Five methods were selected to evaluate the diagnostic reproducibility among 10 investigators, using haematoxylin and eosin (H&E) and AE1-3 cytokeratin-immunostained, whole-slide digital scans from 50 pT1–pT4 colorectal cancers. The overall interobserver agreement was fair for all methods, and increased...
Although tumor budding is linked to adverse prognosis in colorectal cancer, it remains largely unrep...
Tumor budding is recognized by the World Health Organization as an additional prognostic factor in c...
Contains fulltext : 177917pub.pdf (publisher's version ) (Closed access)Tumor budd...
Puppa G, Senore C, Sheahan K, Vieth M, Lugli A, Zlobec I, Pecori S, Wang L M, Langner C, Mitomi H, N...
Tumor budding in colorectal cancer (CRC) is recognized as a valuable prognostic factor but its trans...
Tumor budding in colorectal cancer (CRC) is recognized as a valuable prognostic factor but its trans...
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet ...
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet ...
Cancer represents a formidable health burden and was the second leading cause of death globally in 2...
International audienceAssessment of the risk of lymph node invasion and tumour recurrence is critica...
AIMS: Virtual microscopy offers major advantages for pathology practice, separating slide evaluation...
© 2020 Elsevier GmbH Whole slide imaging (WSI) has recently received FDA approval for sign out in su...
BACKGROUND Tumour budding in colorectal cancer (CRC) is a recognized prognostic parameter. Aim of...
Tumor cell fraction (TCF) estimation is a common clinical task with well-established large inter-obs...
BACKGROUND: The Immunoscore (IS) is a quantitative digital pathology assay that evaluates the immune...
Although tumor budding is linked to adverse prognosis in colorectal cancer, it remains largely unrep...
Tumor budding is recognized by the World Health Organization as an additional prognostic factor in c...
Contains fulltext : 177917pub.pdf (publisher's version ) (Closed access)Tumor budd...
Puppa G, Senore C, Sheahan K, Vieth M, Lugli A, Zlobec I, Pecori S, Wang L M, Langner C, Mitomi H, N...
Tumor budding in colorectal cancer (CRC) is recognized as a valuable prognostic factor but its trans...
Tumor budding in colorectal cancer (CRC) is recognized as a valuable prognostic factor but its trans...
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet ...
Tumor budding is a long-established independent adverse prognostic marker in colorectal cancer, yet ...
Cancer represents a formidable health burden and was the second leading cause of death globally in 2...
International audienceAssessment of the risk of lymph node invasion and tumour recurrence is critica...
AIMS: Virtual microscopy offers major advantages for pathology practice, separating slide evaluation...
© 2020 Elsevier GmbH Whole slide imaging (WSI) has recently received FDA approval for sign out in su...
BACKGROUND Tumour budding in colorectal cancer (CRC) is a recognized prognostic parameter. Aim of...
Tumor cell fraction (TCF) estimation is a common clinical task with well-established large inter-obs...
BACKGROUND: The Immunoscore (IS) is a quantitative digital pathology assay that evaluates the immune...
Although tumor budding is linked to adverse prognosis in colorectal cancer, it remains largely unrep...
Tumor budding is recognized by the World Health Organization as an additional prognostic factor in c...
Contains fulltext : 177917pub.pdf (publisher's version ) (Closed access)Tumor budd...